Apolipoproteins: Metabolic role and clinical biochemistry applications

Annals of Clinical Biochemistry

Volumn 48, Issue 6, 2011, Pages 498-515

  Dominiczak, Marek H ^a   Caslake, Muriel J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN A4; APOLIPOPROTEIN A5; APOLIPOPROTEIN B; APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; APOLIPOPROTEIN C1; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; CHOLESTEROL; CHYLOMICRON; HIGH DENSITY LIPOPROTEIN; INTERMEDIATE DENSITY LIPOPROTEIN; LIPOPROTEIN A; MEMBRANE RECEPTOR; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ALLELE; ALZHEIMER DISEASE; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; DIABETES MELLITUS; DYSLIPIDEMIA; ELECTROIMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME REGULATION; GENETIC CODE; GENOTYPE; IMMUNOBLOTTING; IMMUNODIFFUSION; LIPOLYSIS; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; METABOLIC SYNDROME X; MOLECULAR SIZE; NEPHELOMETRY; OBESITY; PHENOTYPE; POLYACRYLAMIDE GEL ELECTROPHORESIS; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; RADIOIMMUNOASSAY; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; TURBIDIMETRY; ULTRACENTRIFUGATION;

ANIMALS; APOLIPOPROTEINS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM DISORDERS; METABOLIC SYNDROME X; OBESITY; POSTPRANDIAL PERIOD; PROTEIN ISOFORMS;

EID: 84856010494     PISSN: 00045632     EISSN: 17581001     Source Type: Journal    
DOI: 10.1258/acb.2011.011111     Document Type: Review

References (159)

1. Baynes J, Dominiczak MH, eds. Medical Biochemistry. 3rd edn. London: Elsevier Mosby, 2009:653
2. Durrington P. Dyslipidemia. Lancet 2003;362:717-31
3. Rifai N, Warnick GR, Dominiczak MH, eds. Handbook of Lipoprotein Testing. 2nd edn. Washington DC: AACC Press, 2000:817
4. Dominiczak MH. Obesity, glucose intolerance and diabetes and their links to cardiovascular disease. Implications for laboratory medicine. Clin Chem Lab Med 2003;41:1266-78
5. Dominiczak MH. Lipids: the story so far. Br J Cardiol 1997;4:425-9
6. Dominiczak MH. Risk factors for coronary disease: the time for a paradigm shift? Clin Chem Lab Med 2001;39:907-19
7. Olivecrona T, Bengtsson-Olivecrona G. Lipoprotein lipase and hepatic lipase. Curr Opin Lipidol 1990;1:222-30
8. Zambon A, Hokanson JE, Brown BG, Brunzell JD. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation 1999;99:1959-64
9. Rousset X, Vaisman B, Amar M, et al. Lecithin: cholesterol acyltransferase - from biochemistry to role in cardiovascular disease. Curr Opin Endocrinol Diabetes Obes 2009;16:163-71
10. Applebaum-Bowden D. Lipases and lecithin:cholesterol acyltransferase in the control of lipoprotein metabolism. Curr Opin Lipidol 1995;6:130-5
11. Hesler CB, Swenson TL, Tall AR. Purification and characterization of a human plasma cholesterol ester transfer protein. J Biol Chem 1987;262:2275-82
12. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232:34-47
13. Herz J. The LDL-receptor related protein: portrait of a multifunctional receptor. Curr Opin Lipidol 1993;4:107-13
14. Rigotti A, Miettinen HE, Krieger M. The role of the high-density lipoprotein receptor SR-BI in the lipid metabolism of endocrine and other tissues. Endocr Rev 2003;24:357-87
15. Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 2007;116:1832-44
16. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-9
17. Rader DJ, Daugherty A. Translating molecular discoveries into new therapies for atherosclerosis. Nature 2008;451:904-13
18. Dominiczak MH. Apoproteins and lipoproteins in human plasma. In: Rifai N, Warnick GR, Dominiczak MH, eds. Handbook of Lipoprotein Testing. 1st edn. Washington: AACC Press, 1997:1-24
19. Powell LM, Wallis SC, Pease RJ, Edwards YH, Knott TJ, Scott J. A novel form of tissue specific RNA processing produces apolipoprotein B48 in intestine. Cell 1987;50:831-40
20. Eisenberg S, Sehayek E. Remnant particles and their metabolism. Baillieres Clin Endocrinol Metab 1995;9:739-53
21. Cohn JS, Marcoux C, Davignon J. Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins. Arterioscler Thromb Vasc Biol 1999;19:2474-86
22. Mann CJ, Yen FT, Grant AM, Bihain BE. Mechanism of plasma cholesteryl ester transfer in hypertriglyceridaemia. J Clin Invest 1991;88:2059-66
23. Fruchart JC, Ailhaud G. Apolipoprotein A-containing particles: physiological role, quantification and clinical significance. Clin Chem 1992;38:793-7
24. Lee DM, Alaupovic P, Knight-Gibson C, Bagdade JD. Apolipoprotein-B subclasses as acceptors of cholesteryl esters transferred by CETP. Eur J Clin Invest 2008;38:734-42
25. Havel RJ. The formation of LDL: mechanisms and regulation. J Lipid Res 1984;25:1570-6
26. Bruckert E, Hansel B. HDL-C is a powerful lipid predictor of cardiovascular diseases. Int J Clin Pract 2007;61:1905-13
27. von Eckardstein A, Huang Y, Assman G. Physiological role and clinical relevance of high-density lipoprotein subclasses. Curr Opin Lipidol 1994;5:404-16
28. Florentin M, Liberopoulos EN, Wierzbicki AS, Mikhailidis DP. Multiple actions of high-density lipoprotein. Curr Opin Cardiol 2008;23:370-8
29. Austin MA, King MD, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990;82:495-506
30. Austin MA, Edwards KL. Small, dense low density lipoproteins, the insulin resistance syndrome and noninsulin-dependent diabetes. Curr Opin Lipidol 1996;7:167-71
31. Dominiczak MH. Apoproteins and lipoproteins in human plasma. In: Rifai N, Warnick GR, Dominiczak MH, eds. Handbook of Lipoprotein Testing. 2nd edn. Washington DC: AACC Press, 2000:1-29
32. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502
33. Liu J, Sempos CT, Donahue RP, et al. Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease. Am J Cardiol 2006;98:1363-8
34. Shai I, Rimm EB, Harkinson SE, et al. Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines. Circulation 2004;110:2824-30
35. Jiang R, Schulze MB, Li T, et al. Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes. Diabetes Care 2004;27:1991-7
36. Blake GJ, Otvos JD, Rifai N, Ridker PM. Low-density lipoprotein particle concentration and size are determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 2002;106:1930-7
37. Hainline AJ, Karon J, Kippel K. Manual of Laboratory Operations: Lipid Research Clinics Program, Lipid and Lipoprotein Analysis. 2nd edn. Washington, DC: Department of Health and Human Services, 1983
38. Marcovina S, Packard CJ. Measurement and meaning of apolipoprotein B plasma levels. J Intern Med 2006;259:437-46
39. Durrington PN. Hyperlipidaemia: Diagnosis and Treatment. 3rd edn. London: Hodder Arnold, 2007:66-91
40. Olofsson SO, Borèn J. Apolipoprotein B: a clinically important apolipoprotein, which assembles atherogenic lipoproteins and promotes the development of atherosclerosis. J Intern Med 2005;258:395-410
41. Knott TJ, Pease RJ, Powell LM, et al. Complete protein sequence and identification of structural domains of human apolipoprotein B. Nature 1986;323:734-8
42. Hussain MM, Shi J, Dreizen P. Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly. J Lipid Res 2003;44:22-32
43. Blackhart BD, Ludwig EM, Pierotti VR, et al. Structure of the human apolipoprotein B gene. J Biol Chem 1986;261:15364-7
44. Innerarity TL, Mahley TL, Weisgraber KH, et al. Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. J Lipid Res 1990;31:1337-49
45. Hardman DA, Kane JP. Isolation and characterization of apolipoprotein B-48. Methods Enzymol 1986;128:262-72
46. Su JW, Nzekwu MMU, Cabezas MC, Redgrave T, Proctor SD. Methods to assess impaired post-prandial metabolism and the impact for early detection of cardiovascular disease risk. Eur J Clin Invest 2009;39:741-54
47. Berry SEE. Postprandial lipaemia - the influence of diet and its link to coronary heart disease. Nutr Bull 2005;30:314-22
48. Bruns GA, Karathanasis SK, Breslow JL. Human apolipoprotein A-I- C-III gene complex is located on chromosome 11. Arteriosclerosis 1984;4:97-102
49. Feng H, Li X-A. Dysfunctional high-density lipoprotein. Curr Opin Endocrinol Diabetes Obes 2009;16:156-62
50. Kilimov AN, Gurevich VS, Nikiforova AA, et al. Antioxidative activity of high density lipoproteins in vivo. Atherosclerosis 1993;100:13-8
51. Cheung M, Albers JJ. Distribution of high density lipoprotein particles with different apoprotein composition: particles with AI and AII and particles with AI but no AII. J Lipid Res 1982;23:747-53
52. Julve J, Escola'-Gil JC, Rotllan N, et al. A human apolipoprotein AII determines plasma triglycerides by regulating lipoprotein lipase activity and high-density lipoprotein proteome. Arterioscler Thromb Vasc Biol 2010;30:232-8
53. Warden CH, Hedrick CC, Quiao J-H, Castellani LW, Lusis AJ. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. Science 1993;261:469-72
54. Birjmohun RS, Dallinga-Thie GM, Kuivenhoven JA, et al. Apolipoprotein A-II is inversely associated with risk of future coronary disease. Circulation 2007;116:2029-35
55. Tailleux A, Duriez P, Fruchart JC, Clavey V. Apolipoprotein A-II, HDL metabolism and atherosclerosis. Atherosclerosis 2002;164:1-13
56. Weinberg RB. Apolipoprotein A-IV polymorphisms and diet-gene interactions. Curr Opin Lipidol 2002;13:125-34
57. Calandra S, Oliva CP, Tarugi P, Bertolini S. APOA5 and triglyceride metabolism, lesson from human APOA5 deficiency. Curr Opin Lipidol 2006;17:122-7
58. Laurila PP, Naukkarinen J, Kristiansson K, et al. Genetic association and interaction analysis of USF1 and APOA5 on lipid levels and atherosclerosis. Arterioscler Thromb Vasc Biol 2010;30:346-52
59. Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010;375:1634-9
60. Lai C-Q, Parnell LD, Ordovas JM. The APOAI/C3/A4/A5 gene cluster, lipid metabolism and cardiovascular disease risk. Curr Opin Lipidol 2005;16:153-66
61. Chan DC, Chen MM, Ooi EMM, Watts GF. An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor? Int J Clin Pract 2008;62:799-809
62. Kypreos KE, Karagiannides I, Fotiadou EH, et al. Mechanisms of obesity and related pathologies: role of apolipoprotein E in the development of obesity. FEBS J 2009;276:5720-8
63. Mahley RW, Innerarity TL, Rall JSC, Weisgraber KH, Taylor JM. Apolipoprotein E: genetic variants provide insights into its structure and function. Curr Opin Lipidol 1990;1:87-95
64. Donahue JE, Johanson CE. Apolipoprotein E, amyloid-A, and blood- brain barrier permeability in Alzheimer disease. J Neuropathol Exp Neurol 2008;67:261-70
65. Boyles JK, Pitas RE, Wilson E, Mahley RW, Taylor JM. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J Clin Invest 1985;76:1501-13
66. Chroni A, Nieland TJ, Kypreos KE, Krieger M, Zannis VI. SR-BI mediates cholesterol efflux via its interactions with lipid-bound ApoE. Structural mutations in SR-BI diminish cholesterol efflux. Biochemistry 2005;44:13132-43
67. Utermann G. Apolipoprotein E polymorphisms in health and disease. Am Heart J 1987;113:433-40
68. Bennet AM, Di Angelantonio E, Ye Z, et al. Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA 2007;298:1300-11
69. Brewer HB, Zech LA, Gregg RE, Schwartz D, Schaeffer EJ. Type III hyperlipoproteinemia: diagnosis, molecular defects, pathology and treatment. Ann Int Med 1983;98:623-40
70. Huang Y. Mechanisms linking apolipoprotein E isoforms with cardiovascular and neurological diseases. Curr Opin Lipidol 2010;21:337-45
71. Loscalzo J. Lipoprotein(a): a unique risk factor for atherothrombotic disease. Arteriosclerosis 1990;10:672-9
72. Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C. Lp(a) glycoprotein phenotypes. J Clin Invest 1987;80:458-65
73. Rath M, Niendorf A, Reblin T, Dietel M, Krebber H-J, Beisiegel U. Detection and quantification of lipoprotein (a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 1989;9:579-92
74. McLean JW, Tomlinson JE, Kuang W-J, et al. cDNA sequence of human apolipoprotein (a) is homologous to plasminogen. Nature 1987;330:132-7
75. Karadi I, Kostner GM, Gries A, Nimpf J, Romics L, Malle E. Lipoprotein (a) and plasminogen are immunochemically related. Biochim Biophys Acta 1988;960:91-7
76. Loscalzo J, Weinfeld M, Fless G, Scanu AM. Lipoprotein (a), fibrin binding and plasminogen activation. Arteriosclerosis 1990;10:240-5
77. Andrikoula M, McDowell IFW. The contribution of apoB and apoA1 measurements to cardiovascular risk assessment. Diabetes Obes Metab 2008;10:271-8
78. Thompson A, Danesh J. Association between apolipoprotein B, apolipoprotein A1, the apolipoprotein B/A1 ratio and coronary heart disease: a literature-based meta-analysis of prospective studies. J Intern Med 2006;259:481-92
79. Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A1: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med 2004;255:188-205
80. Walldius G, Jungner I, Holme I, et al. High apolipoprotein B, low apolipoprotein A-1, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001;358:2026-33
81. McQueen MJ, Hawken S, Wang X, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 2008;372:224-33
82. Benn M, Nordestgaard BG, Jensen GB, Tybjaerg-Hansen A. Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City Heart Study. Arterioscler Thromb Vasc Biol 2007;27:661-70
83. Lamarche B, Moorjani S, Lupien PJ, et al. Apolipoprotein A-1 and B levels and the risk of ischemic heart disease during a 5 year follow-up of men in the Quebec Cardiovascular Study. Circulation 1996;94:273-8
84. Sierra-Johnson J, Fisher RM, Romero-Corral A, et al. Concentration of apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multi-ethnic US population. Eur Heart J 2009;30:710-7
85. Meisinger C, Loewel H, Mraz W, Koenig W. Prognostic value of apolipoprotein B and A-1 in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg Cohort Study. Eur Heart J 2005;26:271-8
86. The Emerging Risk Factor Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000
87. Gotto AM, Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AF-CAPS/TexCAPS). Circulation 2000;101:477-84
88. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients in cardiometabolic risk: conference report from the American Diabetes Association and the American College of Cardiology Foundation. JACC 2008;51:1512-24
89. Otvos JD, Collins D, Freedman DS, et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favourably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 2006;113:1556-63
90. Dominiczak MH. Metabolic syndrome. CPD Clin Biochem 2004;6:3-9
91. Pitsavos C, Panagiotakos DB, Skoumas J, et al. Risk stratification of apolipoprotein B, apolipoprotein AI and apolipoprotein B/AI ratio on the prevalence of the metabolic syndrome: the ATTICA Study. Angiology 2008;59:335-41
92. Onat A, Hergenc G, Yazc M, Karabulut A, Albayrak S. Serum apolipoprotein B predicts dyslipidaemia, metabolic syndrome and, in women, hypertension and diabetes, independent of markers of central obesity and inflammation. Int J Obes 2007;37:1119-25
93. Teng B, Sniderman AD, Soutar AK, Thompson GR. Metabolic basis of hyperapobetalipoproteinemia. Turnover of apolipoprotein B in low density lipoprotein and its precursors and subfractions compared with normal and familial hypercholesterolemia. J Clin Invest 1986;77:663-72
94. De Graaf J, Couture P, Sniderman A. A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias. Nat Clin Pract Endocrinol Metab 2008;4:608-18
95. Sniderman AD, Faraj M. Apolipoprotein B, apolipoprotein A-I, insulin resistance and the metabolic syndrome. Curr Opin Lipidol 2007;18:633-7
96. Contois JH, McConnell JP, Sethi AA, et al. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem 2009;55:407-19
97. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients in cardiometabolic risk: conference report from the American Diabetes Association and the American College of Cardiology Foundation. JACC 2008;51:1512-24
98. BrownWV, Myers GL, Sniderman A, Evan Stein E. Should we use apoB for risk assessment and as a target for treatment? J Clin Lipidol 2010;4:144-51
99. Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation 1979;60:473-85
100. Patsch JR, Miesenbock G, Hopferwieser T, et al. Relationship of triglyceride metabolism and coronary artery disease. Arterioscler Thromb 1992;12:1336-45
101. Karpe F. Postprandial lipoprotein metabolism and atherosclerosis. J Intern Med 1999;246:341-55
102. Bansal S, Buring JE, Rifai N, et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007;298:309-16
103. Børge G, Nordestgaard BG, Benn M, et al. Nonfasting triglycerides and risk of myocardial infarction, ischaemic heart disease, and death in men and women. JAMA 2007;298:299-308
104. Smith D, Watts GF, Dane-Stewart C, Mamo JC. Post-prandial CM response may be predicted by a single measurement of plasma apolipoprotein B48 in the fasting state. Eur J Clin Invest 1999;29:204-9
105. Onat A, Hergenc G, Ayhan E, et al. Metabolism of serum apolipoprotein C-III in high-density lipoprotein: a key diabetogenic risk factor in Turks. Diabet Med 2009;26:981-8
106. Volcik KA, Barkley RA, Hutchinson RG, et al. Apolipoprotein E polymorphisms predict low density lipoprotein cholesterol levels and carotid artery wall thickness but not incident coronary heart disease in 12,491 ARIC study participants. Am J Epidemiol 2006;164:342-8
107. Elosua R, Demissie S, Cupples LA, et al. Obesity modulates the association among APOE genotype, insulin, and glucose in men. Obes Res 2003;11:1502-8
108. Marques-Vidal P, Bongard V, Ruidavets JB, et al. Obesity and alcohol modulate the effect of apolipoprotein E polymorphism on lipids and insulin. Obes Res 2003;11:1200-6
109. Huang ZH, Reardon CA, Mazzone T. Endogenous ApoE expression modulates adipocyte triglyceride content and turnover. Diabetes 2006;55:3394-402
110. Hofmann SM, Perez-Tilve D, Greer TM, et al. Defective lipid delivery modulates glucose tolerance and metabolic response to diet in apolipoprotein E-deficient mice. Diabetes 2008;57:5-12
111. Gao J, Katagiri H, Ishigaki Y, et al. Involvement of apolipoprotein E in excess fat accumulation and insulin resistance. Diabetes 2007;56: 24-33
112. Hofmann SM, Zhou L, Perez-Tilve D, et al. Adipocyte LDL receptorrelated protein-1 expression modulates postprandial lipid transport and glucose homeostasis in mice. J Clin Invest 2007;117:3271-82
113. Saunders AM, Schmader K, Breitner JCS, et al. Apolipoprotein E allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases. Lancet 1993;342:710-11
114. McCarron MO, Hoffmann KL, DeLong DM, Gray L, Saunders AM, Alberts MJ. Intracerebral hemorrhage outcome: apolipoprotein E genotype, hematoma, and edema volumes. Neurology 1999;53:2176-9
115. Catena C, Novello M, Lapenna R, et al. New risk factors for atherosclerosis in hypertension: focus on the prothrombotic state and lipoprotein (a). J Hypertens 2005;23:1617-31
116. Sechi LA, Kronenberg F, De Carli S, Falleti E, Zingaro L. Association of serum lipoprotein (a) levels and apolipoprotein (a) size polymorphism with target-organ damage in arterial hypertension. JAMA 1997;277:1689-95
117. Danesh J, Collins R, Peto R. Lipoprotein (a) and coronary heart disease: meta-analysis of prospective studies. Circulation 2000;102:1082-5
118. The Emerging Risk Factors Collaboration. Lipoprotein (a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009;302:412-23
119. Bennet A, Di Angelantonio E, Erqou S, et al. Lipoprotein(a) levels and risk of future coronary heart disease. Large-scale prospective data. Arch Intern Med 2008;168:598-60
120. Erqou E, Thompson A, Di Angelantonio E, et al. Apolipoprotein(a) isoforms and the risk of vascular disease. J Am Coll Cardiol 2010;55:2160-7
121. European Atherosclerosis Society (EAS). Consensus Panel Presentation at the Meeting of the European Atherosclerosis Society, Hamburg, 2010
122. Goldhaber SZ. European Atherosclerosis Society screening recommendations for lipoprotein (a) and high-sensitivity C-reactive protein: double standard or failure of evidence-based medicine? Clin Chem 2010;56:1544-6
123. Marcovina SM, Albers JJ, Dati F, Ledue TB, Ritchie RF. International Federation of Clinical Chemistry standardisation project for measurements of apolipoprotein A-I and B. Clin Chem 1991;37:1676-82
124. Marcovina SM, Albers JJ, Kennedy H, Mei JV, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardisation project for measurements of apolipoprotein A-I and B. IV. Comparability of apolipoprotein B values by use of international reference material. Clin Chem 1994;40:586-92
125. Labeur C, Rosseneu M. Immunological assays of apolipoproteins A-II, A-IV, C-I, C-II, and C-III in plasma: methods and applications. In: Rifai N, Warnick GR, Dominiczak MH, eds. Handbook of Lipoprotein Testing. 2nd edn.) Washington DC: AACC Press, 2000:387-400
126. Smith D, Proctor SD, Mamo CLM. A highly sensitive assay for quantitation of apolipoprotein B48 using an antibody to human apolipoprotein B and enhanced chemiluminescence. Ann Clin Biochem 1997;34:185-9
127. Karpe F, Hamsten A. Determination of apolipoproteins B-48 and B-100 in triglyceride-rich lipoproteins by analytical SDS-PAGE. J Lipid Res 1994;35:1311-7
128. Valdivielso P, Puerta S, Rioja J, et al. Postprandial apolipoprotein B48 is associated with asymptomatic peripheral arterial disease: a study in patients with type 2 diabetes and controls. Clin Chim Acta 2010;411:433-7
129. Havel RJ. Remnant lipoproteins as therapeutic targets. Curr Opin Lipidol 2000;11:15-20
130. Nakajima K, Saito T, Tamura A, et al. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apoB-100 and anti apoA-I immunoaffinity mixed gels. Clin Chim Acta 1993;223:53-71
131. Mc Namara J, Shah PK, Nakajima K, et al. Remnant lipoprotein cholesterol and triglyceride reference ranges from the Framingham Study. Clin Chem 1998;44:1224-32
132. Van Hees AMJ, Saris WHM, Dallinga-Thie GMD, Hul GB, Martinez JA. Fasting and postprandial remnant-like particle cholesterol concentration in obese participants is associated with plasma triglycerides, insulin resistance and body fat distribution. J Nutr 2008;138:2399-405
133. McNamara JR, Shah PK, Nakajima JM, et al. Remnant-like particle (RLP) cholesterol is an independent cardiovascular risk factor in women: results from the Framingham Heart Study. Atherosclerosis 2001;154:229-36
134. Chan DC, Watts GF, Barrett PH, et al. Markers of triglyceride-rich lipoprotein remnant metabolism in visceral obesity. Clin Chem 2002;48:278-83
135. Abbasi F, McLaughlin T, Lamendola C, et al. Fasting remnant lipoprotein cholesterol and triglyceride concentrations are elevated in nondiabetic, insulin-resistant, female volunteers. J Clin Endocrinol Metab 1999;84:3903-6
136. Higashi K, Ito T, Nakajima K, et al. Remnant-like particles cholesterol is higher in diabetic patients with coronary artery disease. Metabolism 2001;50:1462-5
137. Miyauchi K, Kayahara N, Ishigami M, et al. Development of homogeneous assay to measure remnant lipoprotein cholesterol. Clin Chem 2007;53:2128-35
138. Nagashima M, Mori Y, Morita R, et al. Remnant lipoprotein cholesterol homogeneous assay (RemL-C) is closely associated with very-low-density lipoprotein remnants:comparison with the immunoseparation assay. Rinsho Byori 2008;56:973-9
139. Yoshida H, Kurosawa H, Hirowatari Y, et al. Characteristic comparison of triglyceride-rich remnant lipoprotein measurement between a new homogenous assay (RemL-C) and a conventional immunoseparation method (RLP-C). Lipids Health Dis 2008;7:18-22
140. Nakajima K, Nakano T, Moon HD, et al. The correlation between TG vs. remnant lipoproteins in the fasting and postprandial plasma of 23 volunteers. Clin Chim Acta 2009;404:124-7
141. Schaeffer EJ. Limitations of automated remnant lipoprotein cholesterol assay for diagnostic use. Clin Chem 2009;55:2061-2
142. Siest G, Pillot T, Régis-Bailly A, et al. Apolipoprotein E: an important gene and protein to follow in laboratory medicine. Clin Chem 1995;41:1068-86
143. Havekes LM, de Knijff P, Beisiegel U, Havinga J, Smit M, Klasen E. A rapid micromethod for apolipoprotein E phenotyping directly in serum. J Lipid Res 1987;28:455-63
144. Hackler R, Schaefer JR, Motznu S, et al. Rapid determination of apolipoprotein E phenotypes from whole plasma by automated electric focusing using PhastSystem and immunofixation. J Lipid Res 1994;35:153-8
145. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545-8
146. Siest G, Schlenck A, Starck M, et al. Apolipoprotein E: laboratory determinations and clinical interest. In: Rifai N, Warnick GR, Dominiczak MH, eds. Handbook of Lipoprotein Testing. 2nd edn. Washington DC: AACC Press, 2000:401-40
147. National Institute on Aging/Alzheimer's Association Working Group. Consensus statement. Apolipoprotein E genotyping in Alzheimer's disease. Lancet 1996;347:1091-5
148. Stephens JW, Sozen MM, Whittall RA, et al. Three novel mutations in the apolipoprotein E gene in a sample of individuals with type 2 diabetes mellitus. Clin Chem 2005;51:119-24
149. Mooijaart SP, Berbea JFP, van Heemst D, et al. ApoE plasma levels and risk of cardiovascular mortality in old age. PLoS Med 2006;3:874-88
150. Schiele F, Vincent-Viry M, Starck M, et al. Apolipoprotein E in apolipoprotein B (apo B)- and non-apo B-containing lipoproteins in 3523 participants in the Stanislas Cohort: biological variation and genotype-specific reference limits. Clin Chem 2002;48:291-300
151. Van Vliet P, Westendorp RGJ, Eikelenboom P, et al. Parental history of Alzheimer disease associated with lower plasma apolipoprotein E levels. Neurology 2009;73:681-7
152. Marcovina SM, Albers JJ, Scanu A, et al. Use of reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein (a). Clin Chem 2000;46:1956-67
153. Danik JS, Rifai N, Buring JE, Ridker PM. Lipoprotein (a), measured with an assay independent of apolipoprotein (a) isoform size, and risk of future cardiovascular events among initially healthy women. JAMA 2006;296:1363-70
154. Sacks FM, Alaupovic P, Moye LA, et al. VLDL, apolipoproteins B, CIII and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 2000;102:1886-92
155. Luc G, Fievet C, Artweiler D, et al. Apolipoproteins CIII and E in ApoB and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. J Lipid Res 1996;37:508-17
156. Chivot L, Mainard F, Bigot E, et al. Logistic discriminant analysis of lipids and apolipoproteins in a population of coronary bypass patients and the significance of apolipoproteins CIII and E. Atherosclerosis 1990;82:205-11
157. Kay RG, Gregory B, Grace PB, Pleasance S. The application of ultra-performance liquid chromatography/tandem mass spectrometry to the detection and quantitation of apolipoproteins in human serum. Rapid Commun Mass Spectrom 2007;21:2585-93
158. Superko HR. Advanced lipoprotein testing and subfractionation are clinically useful. Circulation 2009;119:2383-95
159. Mora S. Advanced lipoprotein testing and subfractionation are not (yet) ready for routine clinical use. Circulation 2009;119:2396-404